Type 1 VWD

Prev
 1 / 21 
Next
Prev
 1 / 21 
Next

Learning objectives

After completing this quiz, the learner should be able to:

  • interpret type 1 VWD as a quantitative pattern that requires clinical context
  • distinguish type 1 VWD from low VWF, type 2 VWD, and type 3 VWD using relational laboratory patterns
  • apply VWF thresholds without treating them as biological cliffs
  • recognize why bleeding phenotype may differ among patients with similar VWF levelsidentify physiologic, genetic, and preanalytical factors that can alter VWF resultsevaluate when desmopressin response, duration, and type 1C clearance patterns matter
  • reassess historical type 1 VWD diagnoses when VWF levels normalize with age

A patient has VWF 36 IU/dL, platelet-dependent VWF activity 34 IU/dL, FVIII 52 IU/dL, and normal multimer distribution. Which interpretation best fits the laboratory pattern?

a
Type 1 VWD or low VWF pattern, depending on bleeding context
This pattern reflects a proportional quantitative reduction in VWF. Antigen and platelet-dependent activity are reduced together, the activity-to-antigen ratio is preserved, FVIII is only mildly reduced, and the multimer pattern is normal. Whether this represents type 1 VWD or low VWF depends on the bleeding phenotype and overall clinical context.
b
Type 2A VWD
Type 2A VWD is characterized by qualitative dysfunction with disproportionately reduced activity and loss of high-molecular-weight multimers.
c
Type 2N VWD
Type 2N VWD is suggested by FVIII that is disproportionately low relative to VWF, not by proportional reductions in antigen and activity.
d
Type 3 VWD
Type 3 VWD is characterized by virtual absence of VWF rather than values in the 30–50 IU/dL range.

Why is a VWF level of 38 IU/dL not sufficient by itself to diagnose clinically meaningful type 1 VWD?

a
VWF assays cannot reliably measure levels below 50 IU/dL.
Modern assays reliably measure values well below 50 IU/dL, although assay quality and preanalytical factors remain important.
b
VWF levels are continuously distributed, and bleeding depends on clinical context.
VWF levels form a continuous distribution across the population. A value of 38 IU/dL may represent clinically important type 1 VWD in one patient and a benign laboratory finding in another. Bleeding history, hemostatic exposure, repeat testing, and physiologic modifiers determine the clinical meaning of the laboratory result.
c
Type 1 VWD always requires an abnormal multimer pattern.
Type 1 VWD usually has a normal multimer distribution because the primary problem is quantity rather than multimer architecture.
d
VWF levels between 30 and 50 IU/dL exclude inherited VWD.
Patients with VWF levels between 30 and 50 IU/dL may meet current diagnostic criteria for type 1 VWD when clinically significant bleeding is present.

Two patients both have a VWF activity of 38 IU/dL. One has minimal bleeding, whereas the other has severe heavy menstrual bleeding, iron deficiency, and delayed post-dental bleeding. What best explains the difference?

a
The second patient must have type 3 VWD.
Type 3 VWD would be characterized by virtual absence of VWF, not a VWF activity of 38 IU/dL.
b
The first patient’s laboratory result must be inaccurate.
Identical VWF levels can legitimately produce very different bleeding phenotypes
c
VWF level contributes to bleeding risk but does not determine phenotype by itself.
Bleeding reflects much more than the VWF level alone. Platelet function, FVIII level, vascular integrity, fibrinolysis, gynecologic factors, medications, comorbidities, and exposure to hemostatic challenges all influence the clinical phenotype.
d
Bleeding phenotype cannot be assessed unless VWF is below 30 IU/dL.
Clinically significant bleeding may occur in patients with VWF levels between 30 and 50 IU/dL.

Which laboratory finding should prompt consideration of type 2 VWD rather than typical type 1 VWD?

a
VWF antigen and platelet-dependent activity are reduced proportionally.
Proportional reduction of antigen and activity is the expected laboratory pattern in type 1 VWD.
b
Normal PT and normal platelet count.
PT and platelet count are commonly normal in both type 1 and many type 2 VWD subtypes.
c
Platelet-dependent VWF activity is disproportionately lower than VWF antigen.
Disproportionately reduced platelet-dependent activity compared with antigen suggests a qualitative VWF defect rather than a simple quantitative deficiency. This pattern should prompt evaluation for a type 2 VWD subtype.
d
VWF levels increase during pregnancy.
VWF commonly rises during pregnancy and does not distinguish between type 1 and type 2 VWD.

A patient with suspected type 1 VWD has normal VWF levels during an acute respiratory infection. What is the best next step?

a
Exclude VWD permanently.
Normal VWF levels obtained during an acute-phase response do not exclude baseline VWD.
b
Diagnose type 3 VWD.
Type 3 VWD is characterized by virtual absence of VWF, not transient normalization.
c
Order only a PT and aPTT.
PT and aPTT are not adequate tests for diagnosing or excluding VWD.
d
Repeat testing when the patient has returned to baseline health.
VWF is an acute-phase reactant. Levels may rise during inflammation, stress, exercise, pregnancy, acute bleeding, and other physiologic states. Repeat testing when the patient is well provides a more accurate assessment of baseline VWF biology.

Which statement best describes the role of ABO blood group in evaluating type 1 VWD?

a
Blood group O lowers average VWF levels but does not determine whether a patient has clinically significant bleeding.
Blood group O is associated with lower average VWF levels, making some individuals more likely to have borderline laboratory values. However, ABO does not determine bleeding phenotype or replace clinical interpretation.
b
Blood group O establishes the diagnosis of type 1 VWD.
Blood group O is common and does not establish the diagnosis of VWD.
c
ABO-specific reference ranges are required before VWD can be diagnosed.
Current diagnostic guidelines do not require ABO-specific reference ranges.
d
Patients with non-O blood groups cannot have low VWF.
Patients with non-O blood groups may still have low VWF or inherited VWD.

A desmopressin trial increases VWF activity from 22 IU/dL to 120 IU/dL at one hour, but the level falls to 38 IU/dL by four hours. What is the most important implication?

a
The patient is fully protected for all future procedures.
A good one-hour response does not guarantee sustained hemostatic protection.
b
The patient may have increased VWF clearance, so the duration of response is clinically important.
A brisk initial response followed by rapid decline suggests increased VWF clearance, often referred to as a type 1C phenotype. The durability of the response is just as important as the peak value when planning treatment.
c
The patient has type 2B VWD.
Type 2B VWD is characterized by increased platelet binding and enhanced low-dose RIPA rather than isolated rapid clearance.
d
Desmopressin should never be used again.
Desmopressin may still be useful in selected situations, provided the timing of its response is taken into account.

A patient diagnosed with type 1 VWD during childhood now has normal VWF antigen and activity at age 65. What is the most appropriate interpretation?

a
The diagnosis should automatically be removed.
Normalization of VWF levels does not automatically erase a well-supported diagnosis.
b
The patient now has type 2 VWD.
Type 2 VWD is a qualitative disorder and is not diagnosed because VWF levels normalize over time.
c
Normal VWF levels prove the original diagnosis was incorrect.
Current laboratory values do not invalidate previous clinical and laboratory evidence of disease.
d
The diagnosis should be reconsidered in light of the patient’s previous laboratory results, bleeding history, and treatment response.
VWF levels often rise with age. A patient whose diagnosis was supported by reproducibly low historical levels, a convincing bleeding phenotype, and appropriate treatment responses may still carry clinically relevant disease despite normalization of laboratory values.

Which statement about bleeding assessment tools (BATs) is most accurate?

a
A normal BAT score excludes type 1 VWD.
A normal BAT score does not exclude VWD, particularly in children or patients who have not yet experienced significant hemostatic challenges.
b
BATs are most useful when interpreted in the context of age, sex, hemostatic exposure, and clinical history.
Bleeding assessment tools provide a structured way to collect bleeding history and are particularly valuable in patients with a low pretest probability of disease. Their results must be interpreted in the context of age, sex, prior treatment, and the patient’s exposure to hemostatic challenges.
c
BATs replace laboratory testing for VWD.
BATs complement laboratory evaluation but do not replace VWF antigen, platelet-dependent activity, and FVIII testing.
d
BATs are useful only in patients with severe VWD.
BATs can be useful across the spectrum of inherited bleeding disorders and are not limited to severe disease.

Which scenario best illustrates an important preanalytical or physiologic pitfall in diagnosing type 1 VWD?

a
Repeated testing at baseline health confirms proportionally reduced VWF antigen and activity.
Repeated testing at baseline health strengthens diagnostic confidence rather than creating diagnostic uncertainty.
b
VWF antigen and platelet-dependent activity are proportionally reduced.
Proportional reduction of antigen and activity is the expected laboratory pattern in type 1 VWD.
c
VWF testing performed during pregnancy is interpreted as excluding baseline type 1 VWD.
Pregnancy is associated with physiologic increases in VWF and FVIII. A normal result obtained during pregnancy may mask an underlying baseline deficiency and should not automatically exclude type 1 VWD.
d
FVIII is measured together with VWF antigen and activity.
Measuring FVIII together with VWF antigen and activity is appropriate and recommended in the initial evaluation.

A patient with type 1 VWD, baseline VWF activity of 42 IU/dL, and a mild bleeding phenotype is scheduled for a dental extraction. Which management principle is most appropriate?

a
The subtype alone determines the treatment plan.
Treatment decisions also depend on bleeding phenotype, previous treatment response, procedure type, and comorbidities.
b
Tranexamic acid alone may be appropriate in selected low-risk patients undergoing minor mucosal procedures.
Management should match the hemostatic challenge rather than rely solely on the diagnostic label. For selected patients with mild bleeding and baseline VWF activity above 30 IU/dL, tranexamic acid alone may be sufficient for minor mucosal procedures.
c
VWF concentrate is required for every invasive procedure.
Many patients with type 1 VWD do not require VWF concentrate for minor procedures.
d
No treatment is ever needed when VWF activity is above 30 IU/dL.
Bleeding risk depends on the clinical situation, not simply on whether the VWF level is above a particular threshold.

Which statement best reflects modern clinical reasoning about type 1 VWD?

a
Low VWF alone establishes the diagnosis.
Low VWF alone does not establish clinically meaningful disease.
b
A normal VWF level later in life always excludes previous type 1 VWD.
VWF levels often increase with age, and normalization does not necessarily invalidate a previous well-supported diagnosis.
c
Type 1 VWD is best diagnosed by integrating laboratory findings, bleeding phenotype, physiologic context, and treatment implications.
Modern diagnosis of type 1 VWD integrates laboratory findings with bleeding history, physiologic modifiers, repeat testing, and anticipated treatment consequences. The diagnosis is relational rather than based on a single laboratory value.
d
Genetic testing is required before diagnosing type 1 VWD. Correct answer: C
Genetic testing is not routinely required for most patients with suspected type 1 VWD and is often uninformative in borderline or low-VWF phenotypes.

Which statement best summarizes treatment logic in type 2 VWD?

a
Treat all type 2 variants the same because they are all qualitative disorders.
The four type 2 subtypes have different mechanisms and different treatment implications.
b
Desmopressin is always first-line therapy in every type 2 subtype.
Desmopressin responsiveness varies among type 2 variants and is generally avoided in type 2B VWD.
c
VWF antigen level alone determines treatment intensity.
Proportional reduction of antigen and activity is more consistent with quantitative deficiency.
d
Base therapy on subtype, bleeding phenotype, previous treatment response, and the hemostatic challenge.
VWF antigen alone does not capture qualitative dysfunction or predict procedural bleeding risk.

Sort each item into the category it most directly supports in evaluating suspected type 1 VWD.

normal multimer distribution with reduced intensity
VWF and platelet-dependent activity reduced proportionally
platelet-dependent activity much lower than VWF
disproportionately low FVIII compared with VWF
borderline low VWF during acute illness recovery
testing performed during pregnancy
Supports typical type 1 pattern
Suggests alternative VWD subtype or disorder
Creates diagnostic uncertainty or need for repeat testing

Match the concept with its best clinical implication.

Normal VWF level with aging
Type 1C VWD
Blood group O
Desmopressin peak may be adequate but short-lived
hould prompt reassessment, not automatic removal of a prior well-supported diagnosis
Helps explain lower baseline VWF but does not determine bleeding phenotype
Correct! Sorry, Incorrect.

Closing Note

Type 1 VWD is not just “low VWF.” It is low VWF interpreted through pattern, history, exposure, physiology, and consequence. The best diagnosis is not the one that worships a threshold. It is the one that helps the patient bleed less.

Prev
 1 / 21 
Next